ALS Phase 2b/3 Trial of MN-166 (Ibudilast) in ALS: Trial Update and Basic Characteristics” (Reference # CTL-21), highlighted the following: Overview of the COMBAT-ALS Clinical Trial: Purpose, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback